Integrating Evolving IO Strategies in Frontline mNSCLC Management

The role of immunotherapy (IO) is expanding in metastatic non-small cell lung cancer (mNSCLC), with new combination regimens rapidly being added to evolving clinical guidelines. This interactive Clinical Case Challenge tests your ability to apply emerging IO treatment strategies in first-line (1L) mNSCLC, including optimizing therapy selection based on biomarker testing results. In this interactive Clinical Case Challenge, you will: Test your knowledge of IO-based treatment strategies for 1L mNSCLC, supported by the most recent clinical guidelines Apply clinical reasoning to real-world patient scenarios to inform regimen selection, including consideration of biomarker status Receive immediate, evidence-based feedback to help refine decision-making in your own practice Gain insight on how your answers compare with your peers. Upon completion, you will receive a concise expert summary of the current combination IO landscape in 1L mNSCLC, including foundational clinical trial data, current guideline-based approaches, and emerging IO combinations, to help you stay up to date as clinical evidence continues to evolve.

Credit & MOC Details

Credit information is provided by the course provider. We recommend confirming credit eligibility with the provider or your licensing board before starting the activity.

Target Specialties

Pricing

Free

Reported to ACCME by the provider

Case study / clinical scenario
Credit · Up to 0.5 credits
MOC · Up to 0.5 points
Commercial Support

Released

Jun 18, 2026
Last day to claim credit

Jun 18, 2027 8 months left

Integrating Evolving IO Strategies in Frontline mNSCLC Management

Related courses

More from PRIME Education, Inc. (PRIME®)